Jiangsu Yahong Meditech Co., Ltd. (SHA:688176)

Market Cap	6.71B +80.8%
Revenue (ttm)	279.02M +86.4%
Net Income	-362.17M
EPS	-0.64
Shares Out	562.50M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,464,631
Average Volume	10,551,954
Open	11.94
Previous Close	11.93
Day's Range	11.87 - 12.28
52-Week Range	6.80 - 14.83
Beta	0.68
RSI	42.11
Earnings Date	Apr 18, 2026

About Jiangsu Yahong Meditech

Jiangsu Yahong Meditech Co., Ltd., a pharmaceutical company, focuses on urogenital tumors and women's health in China and internationally. It develops APL-1702, a photodynamic therapy product for the treatment of high-grade squamous intraepithelial lesions of the cervix, as well as for HPV virus clearance indication; APL-1706 and APLD-2304 for non-muscle invasive bladder cancer (NMIBC) diagnosis and surgery indication; APL-1202, an oral reversible MetAP2 inhibitor for untreated intermediate-risk NMIBC and neoadjuvant therapy before muscle-invas...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2010
• Employees: 399
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688176

Financial Performance

In 2024, Jiangsu Yahong Meditech's revenue was 201.56 million, an increase of 1365.55% compared to the previous year's 13.75 million. Losses were -384.06 million, -4.09% less than in 2023.